BGLC — Bionexus Gene Lab Income Statement
0.000.00%
Last trade - 00:00- $4.83m
- $3.25m
- $9.51m
Annual income statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 11.4 | 13.4 | 10.9 | 9.77 | 9.51 |
| Cost of Revenue | |||||
| Gross Profit | 1.72 | 2.27 | 1.26 | 1.33 | 1.29 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.1 | 12.3 | 11.2 | 12.4 | 11.1 |
| Operating Profit | 1.26 | 1.04 | -0.304 | -2.61 | -1.57 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 1.26 | 1.04 | -0.304 | -2.61 | -1.59 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 1.09 | 0.752 | -0.356 | -2.63 | -1.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 1.09 | 0.752 | -0.356 | -2.63 | -1.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 1.09 | 0.752 | -0.356 | -2.63 | -1.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.28 | 0.527 | -0.247 | -1.66 | -0.883 |